Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Delstrigo
Delstrigo 100 mg/300 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-141153 · Präparat HOS-098610
Co-administration of doravirine/lamivudine/tenofovir disoproxil with other moderate CYP3A inducers
has not been evaluated, but decreased doravirine concentrations are expected. If co-administration
with other moderate CYP3A inducers (e.g., debrafenib, lesinurad, bosentan, thioridazine, nafcillin,
modafinil, telotristat ethyl) cannot be avoided, a 100 mg dose of doravirine should be administered
daily, approximately 12 hours after the administration of doravirine/lamivudine/tenofovir disoproxil
dose (see section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): modafinil (HOS-090546) thioridazine (HOS-086281) lesinurad (HOS-141154) telotristat ethyl (HOS-141158) nafcillin (HOS-125452) bosentan (HOS-086291)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T17:24:00Z · SHA-256 2c0deb57aeb6310e5014ea9012afd45619de92a00e9950f55a0cfcc2fdcdf2a8 · Passage c48e6605233c8bf669bd61de34439942f931ab0fb0e47d11e07b242e1b2e4da2 · Zeichen 1442–1964 im Abschnitt
Wechselwirkungen · Delstrigo
Delstrigo 100 mg/300 mg/245 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8–9
HOS-141183 · Präparat HOS-098610
8
Recommendation concerning
Medicinal product by Effects on medicinal product levels co-administration with
therapeutic area geometric mean ratio (90 % CI)* doravirine/lamivudine/tenofovir
disoproxil
Anticonvulsants
Interaction not studied with
carbamazepine doravirine or
oxcarbazepine doravirine/lamivudine/tenofovir
phenobarbital disoproxil. Co-administration is
phenytoin contraindicated.
Expected:
doravirine
(Induction of CYP3A)
Antidiabetics
metformin metformin
(1 000 mg SD, AUC 0.94 (0.88, 1.00) No dose adjustment is required.
doravirine 100 mg QD) Cmax 0.94 (0.86, 1.03)
Interaction not studied with
doravirine or
doravirine/lamivudine/tenofovir
canagliflozin disoproxil.
liraglutide No dose adjustment is required.
sitagliptin Expected:
canagliflozin
liraglutide
sitagliptin
Antidiarrhoeals
Interaction not studied with
Co-administration should be
telotristat ethyl doravirine or
avoided. If co-administration
doravirine/lamivudine/tenofovir
cannot be avoided, a 100 mg dose
disoproxil.
of doravirine should be taken
daily, 12 h after the dose of
Expected:
doravirine/lamivudine/tenofovir
↓ doravirine
disoproxil.
(Induction of CYP3A)
Antigout and uricosuric agents
Interaction not studied with Co-administration should be
doravirine or avoided. If co-administration
doravirine/lamivudine/tenofovir cannot be avoided, a 100 mg dose
lesinurad disoproxil. of doravirine should be taken
daily, approximately 12 h after the
Expected: dose of
↓ doravirine doravirine/lamivudine/tenofovir
(Induction of CYP3A) disoproxil.
Antimycobacterials
doravirine
AUC 0.91 (0.78, 1.06)
Single dose rifampicin
Cmax 1.40 (1.21, 1.63)
(600 mg SD,
C24 0.90 (0.80, 1.01)
doravirine 100 mg SD)
Co-administration is
doravirine contraindicated.
Multiple dose rifampicin
AUC 0.12 (0.10, 0.15)
(600 mg QD,
doravirine 100 mg SD) Cmax 0.43 (0.35, 0.52)
C24 0.03 (0.02, 0.04)
(Induction of CYP3A)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) canagliflozin (HOS-128091) phenobarbital (HOS-085617) carbamazepine (HOS-085618) lesinurad (HOS-141154) telotristat ethyl (HOS-141158) liraglutide (HOS-121332) oxcarbazepine (HOS-110224) sitagliptin (HOS-117222) phenytoin (HOS-084531) metformin (HOS-091032)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T17:24:00Z · SHA-256 2c0deb57aeb6310e5014ea9012afd45619de92a00e9950f55a0cfcc2fdcdf2a8 · Passage f68b6403660140b1f1202214ec0288cfecb2d5e8a3212a3a1a86ea3eb82a2723 · Zeichen 8245–12384 im Abschnitt
Wechselwirkungen · Pifeltro
Pifeltro 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-141250 · Präparat HOS-098618
Co-administration of doravirine with other moderate CYP3A inducers has not been evaluated, but
decreased doravirine concentrations are expected. If co-administration with other moderate CYP3A
inducers (e.g., dabrafenib, lesinurad, bosentan, thioridazine, nafcillin, modafinil, telotristat ethyl)
cannot be avoided, the doravirine dose should be increased to 100 mg twice daily (the doses should be
taken approximately 12 hours apart) (see section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): modafinil (HOS-090546) thioridazine (HOS-086281) lesinurad (HOS-141154) dabrafenib (HOS-109452) telotristat ethyl (HOS-141158) nafcillin (HOS-125452) bosentan (HOS-086291)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T08:41:00Z · SHA-256 e669d0797aaecb09c38b8d2518d46b353834062d76517638eed9a33ed2fd94be · Passage 0717ae26b7f0a6df8151413269138f674ce7c478fda7218a21d69ec8a18ad152 · Zeichen 788–1240 im Abschnitt
Wechselwirkungen · Pifeltro
Pifeltro 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5–6
HOS-141259 · Präparat HOS-098618
5
Medicinal product by Effects on medicinal product Recommendation concerning
therapeutic area levels geometric mean ratio co-administration with
(90 % CI)* doravirine
Anticonvulsants
carbamazepine Interaction not studied.
oxcarbazepine
Co-administration is
phenobarbital Expected:
contraindicated.
phenytoin doravirine
(Induction of CYP3A)
Antidiabetics
metformin metformin
(1 000 mg SD, AUC 0.94 (0.88, 1.00) No dose adjustment is required.
doravirine 100 mg QD) Cmax 0.94 (0.86, 1.03)
Interaction not studied.
canagliflozin
Expected:
liraglutide No dose adjustment is required.
↔ canagliflozin
sitagliptin
↔ liraglutide
↔ sitagliptin
Antidiarrhoeals
Interaction not studied. Co-administration should be
avoided. If co-administration
Expected: cannot be avoided, one tablet of
telotristat ethyl
↓ doravirine doravirine should be taken twice
(Induction of CYP3A) daily (approximately 12 hours
apart).
Antigout and uricosuric agents
Interaction not studied. Co-administration should be
avoided. If co-administration
Expected: cannot be avoided, one tablet of
lesinurad
↓ doravirine doravirine should be taken twice
(Induction of CYP3A) daily (approximately 12 hours
apart).
Antimycobacterials
Single dose rifampicin doravirine
(600 mg SD, AUC 0.91 (0.78, 1.06)
doravirine 100 mg SD) Cmax 1.40 (1.21, 1.63)
C24 0.90 (0.80, 1.01)
Co-administration is
Multiple dose rifampicin doravirine contraindicated.
(600 mg QD, AUC 0.12 (0.10, 0.15)
doravirine 100 mg SD) Cmax 0.43 (0.35, 0.52)
C24 0.03 (0.02, 0.04)
(Induction of CYP3A)
Interaction not studied.
Co-administration is
rifapentine Expected:
contraindicated.
doravirine
(Induction of CYP3A)
doravirine If doravirine is co-administered
rifabutin AUC 0.50 (0.45, 0.55) with rifabutin, the doravirine dose
(300 mg QD, Cmax 0.99 (0.85, 1.15) should be increased to 100 mg
doravirine 100 mg SD) C24 0.32 (0.28, 0.35) twice daily (approximately
(Induction of CYP3A) 12 hours apart).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): canagliflozin (HOS-128091) phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifabutin (HOS-086262) lesinurad (HOS-141154) telotristat ethyl (HOS-141158) liraglutide (HOS-121332) rifapentine (HOS-116386) oxcarbazepine (HOS-110224) sitagliptin (HOS-117222) phenytoin (HOS-084531) metformin (HOS-091032)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-19T08:41:00Z · SHA-256 e669d0797aaecb09c38b8d2518d46b353834062d76517638eed9a33ed2fd94be · Passage b6c007477c17e1b76ceb7164860101b6c785fb58cc8d8fa8c9e4cb468184eaeb · Zeichen 5245–9123 im Abschnitt
Wechselwirkungen · Truqap
TRUQAP 160 mg film-coated tablets TRUQAP 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-150761 · Präparat HOS-100380
Moderate CYP3A4 inducers
Co-administration of capivasertib with moderate CYP3A4 inducer has the potential to decrease the
concentration of capivasertib. This may reduce the efficacy of TRUQAP. Co-administration of
moderate CYP3A4 inducers should be avoided (e.g. bosentan, cenobamate, dabrafenib, elagolix,
etravirine, lersivirine, lesinurad, lopinavir, lorlatinib, metamizole, mitapivat, modafinil, nafcillin,
pexidartinib, phenobarbital, rifabutin, semagacestat, sotorasib, talviraline, telotristat ethyl,
thioridazine).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lopinavir (HOS-086269) phenobarbital (HOS-085617) modafinil (HOS-090546) rifabutin (HOS-086262) thioridazine (HOS-086281) sotorasib (HOS-147831) etravirine (HOS-088088) lesinurad (HOS-141154) dabrafenib (HOS-109452) telotristat ethyl (HOS-141158) mitapivat (HOS-147878) nafcillin (HOS-125452) elagolix (HOS-112109) lorlatinib (HOS-140195) bosentan (HOS-086291) pexidartinib (HOS-150766) cenobamate (HOS-146930)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-06T12:20:00Z · SHA-256 b060cde010dec5d14aa99becadb87be90da15add7354e09540675f70797404c4 · Passage 43e09a1183a46dece579329742c5c42c18ba144104961e5110d22330aa49be6a · Zeichen 1888–2410 im Abschnitt
Wechselwirkungen · Balversa
Balversa 3 mg film-coated tablets Balversa 4 mg film-coated tablets Balversa 5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-151047 · Präparat HOS-100442
Strong or moderate CYP3A4 inducers
Co-administration with carbamazepine, a strong CYP3A4 and weak CYP2C9 inducer leads to
decreased erdafitinib exposure. Mean ratios of Cmax and AUC∞ for erdafitinib was 65.4% (90% CI:
60.8, 70.5) and 37.7% (90% CI: 35.4, 40.2), respectively, when co-administered with carbamazepine
relative to erdafitinib alone. Avoid co-administration of Balversa with strong CYP3A4 inducers (such
as apalutamide, enzalutamide, lumacaftor, ivosidenib, mitotane, rifapentine, rifampicin,
carbamazepine, phenytoin, and St. John’s wort). If Balversa is co-administered with a moderate
CYP3A4 inducer (such as dabrafenib, bosentan, cenobamate, elagolix, efavirenz, etravirine, lorlatinib,
mitapivat, modafinil, pexidartinib, phenobarbital, primidone, repotrectinib, rifabutin, sotorasib,
telotristat ethyl), the dose should be cautiously increased by 1 to 2 mg and adjusted gradually every
two to three weeks based on clinical monitoring for adverse reactions, not to exceed 9 mg. If the
moderate CYP3A4 inducer is discontinued, the Balversa dose may be adjusted as tolerated (see
sections 4.2 and 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lumacaftor (HOS-139029) phenobarbital (HOS-085617) modafinil (HOS-090546) carbamazepine (HOS-085618) rifabutin (HOS-086262) apalutamide (HOS-086212) sotorasib (HOS-147831) etravirine (HOS-088088) dabrafenib (HOS-109452) telotristat ethyl (HOS-141158) mitapivat (HOS-147878) mitotane (HOS-112479) elagolix (HOS-112109) lorlatinib (HOS-140195) rifapentine (HOS-116386) ivosidenib (HOS-112046) efavirenz (HOS-087947) bosentan (HOS-086291) phenytoin (HOS-084531) repotrectinib (HOS-151068) enzalutamide (HOS-116829) pexidartinib (HOS-150766) cenobamate (HOS-146930) primidone (HOS-090551)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-23T15:29:41Z · SHA-256 9ba94a293568a63e1d68e3b08064d69d982961a4e8105cf8a7ed2e20ea28400b · Passage 37f802579316593a43bdb4de7805a7ac6e6865a9f601ae60d32e15b61a221f1c · Zeichen 1417–2535 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.